Yodantipyrine - instructions for use, dose, side effects, contraindications

Active substanceIodofenazoneIodofenazone

Similar drugsTo uncover

Yodantipyrine

pills inwards

Science Technics Medicine, LLC Russia

Yodantipyrine

pills inwards

UPDATE OF PFC, CJSC Russia

Dosage form: & nbsppills

Composition:

Active substance: iodophenazone (iodantipyrine) 100 mg;

Excipients: potato starch, dextrose, magnesium stearate.

Description:

Tablets are white or almost white in color, odorless or with a weak specific smell, flat-cylindrical with a facet on both sides.

Pharmacotherapeutic group:Antiviral agent

ATX: & nbsp

J.05.A.X Other antiviral drugs

Pharmacodynamics:

Yodantipirin has anti-inflammatory, immunostimulating and interferonogenic properties. Stabilizes biological membranes and delays the penetration of the virus into the cell. It is an active inducer of alpha and beta interferon, stimulates cellular and humoral immunity. It is active against tick-borne encephalitis virus and hemorrhagic fever with renal syndrome.

Pharmacokinetics:

Quickly absorbed from the gastrointestinal tract, bioavailability is 80%. Up to 95% is metabolized in the liver. Urinary excretion through the kidneys by active transport into the renal tubules: 3-5% unchanged, 80-95% - in the form of inactive metabolites. Has a high affinity for tissue proteins.In therapeutic concentrations, rapidly passes from plasma albumin with a maximum concentration in the tissues after 10-12 hours. Binding to plasma proteins is 25%. Half-life is about 6 hours.

Indications:Treatment and prevention of tick-borne encephalitis.

Treatment of hemorrhagic fever with renal syndrome (as part of complex therapy).

Contraindications:

Individual intolerance of Yodantipirin and other iodine-containing drugs, hyperthyroidism, renal, hepatic insufficiency, pregnancy, lactation period, children's age.

Dosing and Administration:

Inside, after eating.

Prophylaxis and treatment of tick-borne encephalitis

Treatment:

- 0.3 g (3 tablets) - 3 times a day for the first 2 days;

- 0.2 g (2 tablets) - 3 times a day for the next 2 days;

- for 0.1 g (1 tablet) - 3 times a day for the next 5 days.

Prevention:

a) after tick sucking:

- 0.3 g (3 tablets) - 3 times a day for the first 2 days;

- 0.2 g (2 tablets) - 3 times a day for the next 2 days;

- for 0.1 g (1 tablet) - 3 times a day for the next 5 days.

b) during the period of stay in places associated with the possible sucking of ticks:

- 0.2 g (2 tablets) - once a day for the whole period;

- 0.2 g (2 tablets) - 3 times a day for 2 days before visiting places associated with the possible sucking of ticks.

Treatment of hemorrhagic fever with renal syndrome (HFRS):

The drug should be prescribed within five days from the onset of the disease:

- 0.2 g (2 tablets) - 3 times a day for the first 4 days, then

- for 0.1 g (1 tablet) - 3 times a day for the next 5 days.

Side effects:

Dyspepsia, skin rash, itching, angioedema.

Interaction:

Antacids and blockers H₂-receptors reduce the absorption of the drug and its effect.

When combined with oral gipoglikemicheskie drugs, barbiturates, tricyclic antidepressants, anticoagulants of indirect action, Yodantipirin enhances their action, displacing them from the connection with proteins.

Special instructions:

In the treatment and prevention of tick-borne encephalitis, joint use of Iodantipyrin and anti-malignant immunoglobulin is not recommended.

In focal forms of tick-borne encephalitis, a specific immunoglobulin is initially administered according to the usual scheme and after 2-3 days Yodantipirin is administered in the indicated dosages.

Form release / dosage:

Tablets, 100 mg.

Packaging:

For 10 tablets in a contour non-jawed package.

10 tablets per contour cell pack.

For 50 tablets in cans of glass.

Each jar or 2, 5 contour non-jawed or contour mesh packages with instructions for use in the pack.

Storage conditions:

In a dry, dark place, out of the reach of children, at a temperature of no higher than 25 ° C.

Shelf life:

2 years.

Do not use after the time specified on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-000055/08

Date of registration:17.01.2008

Expiration Date:Unlimited

The owner of the registration certificate:UPDATE OF PFC, CJSC UPDATE OF PFC, CJSC Russia

Manufacturer: & nbsp

UPDATE, PFC CJSC Russia

Representation: & nbspUPDATE OF PFC, CJSCUPDATE OF PFC, CJSC

Information update date: & nbsp18.11.2017

Illustrated instructions

Instructions

Yodantipyrine (Iodantipyrin)